Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome.
Schweiz
bioMérieux and Knome Sign Strategic Partnership
21 April, 2010
bioMérieux Introduces Myla™ at ECCMID: New Informatics Solution to Transform the Microbiology Laboratory
12 April, 2010
Innovative software: consolidates and transforms microbiology laboratory data into actionable information for treatment decisions recaptures time for lab managers through efficiency gains and full control of lab workflow A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. For more information, visit www.mylahelps.com.
bioMérieux Acquires from AnagnosTec - Database and Expertise for Rapid Microbial Identification Using Mass Spectrometry
12 April, 2010
bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology.
bioMérieux’s PREVI™ Isola Wins the 2010 - Medical Design Excellence Award
08 April, 2010
The award highlights the automated media streaker’s breakthrough technology. A world leader in in vitro diagnostics, bioMérieux announced today that its automated media streaker, PREVI™ Isola has received a 2010 Medical Design Excellence Award for contributions and advances in the design of medical products. This exclusive award recognizes products for their design and engineering features, including user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. PREVI Isola was designed to revolutionize front-end media processing tasks, and it is a critical component in bioMérieux’s complete range of solutions and services for Full Microbiology Lab Automation (FMLA™)
Philips and bioMérieux announce partnership to develop and market next-generation handheld diagnostic solutions for Point-of-Care
07 Januar, 2010
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)).
bioMérieux’s TEMPO® Gains Approval for Testing E. coli in Food Samples
01 Dezember, 2009
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
17 November, 2009
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.
New A(H1N1) Strain Added to bioMérieux’s Molecular Diagnostic Test NucliSENS EasyQ® Influenza A/B
12 November, 2009
A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain.